|
1
|
Han Y, Jia C, Cong X, Yu F, Cai H, Fang S,
Cai L, Yang H, Sun Y, Li D, et al: Increased expression of TGFβR2
is associated with the clinical outcome of non-small cell lung
cancer patients treated with chemotherapy. PLoS One.
10:e01346822015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meng W, Ye Z, Cui R, Perry J,
Dedousi-Huebner V, Huebner A, Wang Y, Li B, Volinia S, Nakanishi H,
et al: MicroRNA-31 predicts the presence of lymph node metastases
and survival in patients with lung adenocarcinoma. Clin Cancer Res.
19:5423–5433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mitra R, Edmonds MD, Sun J, Zhao M, Yu H,
Eischen CM and Zhao Z: Reproducible combinatorial regulatory
networks elucidate novel oncogenic microRNAs in non-small cell lung
cancer. RNA. 20:1356–1368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang L, Wang XF, Ma YS, Xia Q, Zhang F,
Fu D and Wang YC: Quantitative assessment of the influence of TP63
gene polymorphisms and lung cancer risk: Evidence based on 93,751
subjects. PLoS One. 9:e870042014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shen S, Yue H, Li Y, Qin J, Li K, Liu Y
and Wang J: Upregulation of miR-136 in human non-small cell lung
cancer cells promotes Erk1/2 activation by targeting PPP2R2A. Tumor
Biol. 35:631–640. 2014. View Article : Google Scholar
|
|
6
|
Fang Y, Fu D and Shen XZ: The potential
role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim
Biophys Acta. 1806:1–6. 2010.PubMed/NCBI
|
|
7
|
Agirre X, Vilas-Zornoza A, Jiménez-Velasco
A, Martin-Subero JI, Cordeu L, Gárate L, José-Eneriz San E,
Abizanda G, Rodríguez-Otero P, Fortes P, et al: Epigenetic
silencing of the tumor suppressor microRNA hsa-miR-124a regulates
CDK6 expression and confers a poor prognosis in acute lymphoblastic
leukemia. Cancer Res. 69:4443–4453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pierson J, Hostager B, Fan R and Vibhakar
R: Regulation of cyclin dependent kinase 6 by microRNA 124 in
medulloblastoma. J Neurooncol. 90:1–7. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li JQ, Hu SY, Wang ZY, Lin J, Jian S, Dong
YC, Wu XF, Lan D and Cao LJ: MicroRNA-125-5p targeted CXCL13: A
potential biomarker associated with immune thrombocytopenia. Am J
Transl Res. 15:772–780. 2015.
|
|
10
|
Xie J, Yu F, Li D, Zhu X, Zhang X and Lv
Z: MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in
non-small cell lung cancer by targeting RUNX2. Tumor Biol.
37:1197–1204. 2016. View Article : Google Scholar
|
|
11
|
Zhou YL, Xu YJ and Qiao CW: miR-34c-3p
suppresses the proliferation and invasion of non-small cell lung
cancer (NSCLC) by inhibiting PAC1/MAPK pathway. Int J Clin Exp
Pathol. 8:6312–6322. 2015.PubMed/NCBI
|
|
12
|
Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D
and Chen J: The challenges and the promise of molecular targeted
therapy in malignant gliomas. Neoplasia. 17:239–255. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hashiguchi Y, Nishida N, Mimori K, Sudo T,
Tanaka F, Shibata K, Ishii H, Mochizuki H, Hase K, Doki Y and Mori
M: Down-regulation of miR-125a-3p in human gastric cancer and its
clinicopathological significance. Int J Oncol. 40:1477–1482.
2012.PubMed/NCBI
|
|
14
|
Ruike Y, Ichimura A, Tsuchiya S, Shimizu
K, Kunimoto R, Okuno Y and Tsujimoto G: Global correlation analysis
for micro-RNA and mRNA expression profiles in human cell lines. J
Hum Genet. 53:515–523. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X
and Wang H: miR-125a-3p targets MTA1 to suppress NSCLC cell
proliferation, migration, and invasion. Acta Biochim Biophys Sin
(Shanghai). 47:496–503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raponi M, Dossey L, Jatkoe T, Wu X, Chen
G, Fan H and Beer DG: MicroRNA classifiers for predicting prognosis
of squamous cell lung cancer. Cancer Res. 69:5776–5783. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang L, Huang Q, Zhang S, Zhang Q, Chang
J, Qiu X and Wang E: hsa-miR-125a-3p and hsa-miR-125a-5p are
downregulated in non-small cell lung cancer and have inverse
effects on invasion and migration of lung cancer cells. BMC Cancer.
10:3182010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li W, Duan R, Kooy F, Sherman SL, Zhou W
and Jin P: Germline mutation of microRNA-125a is associated with
breast cancer. J Med Genet. 46:358–360. 2008. View Article : Google Scholar
|
|
20
|
Bi Q, Tang S, Xia L, Du R, Fan R, Gao L,
Jin J, Liang S, Chen Z, Xu G, et al: Ectopic expression of miR-125a
inhibits the proliferation and metastasis of hepatocellular
carcinoma by targeting MMP11 and VEGF. PLoS One. 7:e401692012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo
Z, Dong W, Huang J and Lin T: MicroRNA-125b suppresses the
development of bladder cancer by targeting E2F3. Int J Cancer.
128:1758–1769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tong Z, Liu N, Lin L, Guo X, Yang D and
Zhang Q: miR-125a-5p inhibits cell proliferation and induces
apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1.
Biomed Pharmacother. 75:129–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ninio-Many L, Grossman H, Levi M, Zilber
S, Tsarfaty I, Shomron N, Tuvar A, Chuderland D, Stemmer SM,
Ben-Aharon I and Shalgi R: MicroRNA miR-125a-3p modulates molecular
pathway of motility and migration in prostate cancer cells.
Oncoscience. 1:250–261. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kojima M, Sudo H, Kawauchi J, Takizawa S,
Kondou S, Nobumasa H and Ochiai A: MicroRNA markers for the
diagnosis of pancreatic and biliary-tract cancers. PLoS One.
10:e01182202015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hisaoka M, Matsuyama A, Nagao Y, Luan L,
Kuroda T, Akiyama H, Kondo S and Hashimoto H: Identification of
altered microRNA expression patterns in synovial sarcoma. Genes
Chromosomes Cancer. 50:137–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Della VittoriaScarpati G, Falcetta F,
Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK,
D'Incalci M, De Placido S and Pepe S: A specific miRNA signature
correlates with complete pathological response to neoadjuvant
chemoradiotherapy in locally advanced rectal cancer. Int J Radiat
Oncol Biol Phys. 83:1113–1119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chonglei Bi, Chung TH, Huang G, Zhou J,
Yan J, Gregory JA, Fonseca R and Chng WJ: Genome-wide pharmacologic
unmasking identifies tumor suppressive microRNAs in multiple
myeloma. Oncotarget. 6:26508–26518. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu X, Jia R, Zhou Y, Song X, Wang J, Qian
G, Ge S and Fan X: Microarray-based analysis: Identification of
hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol.
38:1385–1393. 2011.PubMed/NCBI
|
|
29
|
Jiang L, Chang J, Zhang Q, Sun L and Qiu
X: MicroRNA hsa-miR-125a-3p activates p53 and induces apoptosis in
lung cancer cells. Cancer Invest. 31:538–544. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou DH, Wang X and Feng Q: EGCG enhances
the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC
A549 cells. Nutr Cancer. 66:636–644. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang B, Luo W, Sun L, Zhang Q, Jiang L,
Chang J, Qiu X and Wang E: miRNA-125a-3p is a negative regulator of
the RhoA-actomyosin pathway in A549 cells. Int J Oncol.
42:1734–1742. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X
and Wang H: miR-125a-3p targets MTA1 to suppress NSCLC cell
proliferation, migration and invasion. Acta Biochim Biophys Sin
(Shanghai). 47:496–503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li M, Zhang Q, Wu L, Jia C, Shi F, Li S,
Peng A, Zhang G, Song X and Wang C: Serum miR-499 as a novel
diagnostic and prognostic biomarker in non-small cell lung cancer.
Oncol Rep. 31:1961–1967. 2014.PubMed/NCBI
|
|
34
|
Zhou DH, Wang X and Feng Q: EGCG enhances
the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC
A549 cells. Nutr Cancer. 66:636–644. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu FX, Su YL, Zhang H, Kong JY, Yu H and
Qian BY: Prognostic implications for high expression of miR-25 in
lung adenocarcinomas of female non-smokers. Asian Pac J Cancer
Prev. 15:1197–1203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu T, Liu X, Han L, Shen H, Liu L and Shu
Y: Up-regulation of miR-9 expression as a poor prognostic biomarker
in patients with non-small cell lung cancer. Clin Transl Oncol.
16:469–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang M, Zhang Q, Wang J and Zhai Y:
MicroRNA-498 is downregulated in non-small cell lung cancer and
correlates with tumor progression. J Cancer Res Ther. 11 Suppl
1:S107–S111. 2015. View Article : Google Scholar
|
